Corcept Therapeutics gains FDA nod for ovarian cancer drug Lyforli, boosting growth outlook.

Corcept Therapeutics received early FDA approval for Lyforli (relacorilant) combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, marking a significant milestone. The company anticipates further growth from potential European approval, new cancer indications, and ongoing studies including a triple-combo with Avastin. Additionally, promising Phase 2 results for dazucorilant in ALS support a planned Phase 3 trial. Corcept raised its 2026 revenue forecast to $950–$1,050 million, driven by strong sales of Lyforli and Korlym, though risks remain from EU approval uncertainties and pricing pressures.